Chiara Ambrogio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9155200/publications.pdf

Version: 2024-02-01

51 papers	3,468 citations	159585 30 h-index	197818 49 g-index
52 all docs	52 docs citations	52 times ranked	6285 citing authors

#	Article	IF	Citations
1	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood, 2022, 139, 717-731.	1.4	22
2	Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities ofKRASMutations in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 1640-1650.	7.0	19
3	How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2022, 103, 102335.	7.7	19
4	Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. Gastroenterology, 2022, 162, 1242-1255.e11.	1.3	4
5	Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends in Cancer, 2021, 7, 410-429.	7.4	13
6	Discoveries in the redox regulation of KRAS. International Journal of Biochemistry and Cell Biology, 2021, 131, 105901.	2.8	2
7	ERK Inhibitor LY3214996-Based Treatment Strategies forRAS-Driven Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 641-654.	4.1	16
8	A structural model of a Rasâ€“Raf signalosome. Nature Structural and Molecular Biology, 2021, 28, 847-857.	8.2	44
9	A LIBRETTO to orchestrate targeted therapy. Nature Cancer, 2020, 1, 1038-1040.	13.2	1
10	KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2020, 80, 3719-3731.	0.9	30
11	Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. JCI Insight, 2020, 5, .	5.0	16
12	An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. EBioMedicine, 2019, 49, 106-117.	6.1	20
13	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clinical Cancer Research, 2019, 25, 158-165.	7.0	81
14	Wiskottâ€“Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nature Medicine, 2019, 25, 130-140.	30.7	57
15	A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance. Cell Adhesion and Migration, 2018, 12, 1-4.	2.7	9
16	An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant toÂDabrafenib Plus Trametinib. Journal of Thoracic Oncology, 2018, 13, e131-e133.	1.1	30
17	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell, 2018, 172, 857-868.e15.	28.9	220
18	Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma. Current Medicinal Chemistry, 2018, 25, 558-574.	2.4	11

#	Article	IF	Citations
19	Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. Translational Lung Cancer Research, 2018, 7, 487-497.	2.8	45
20	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clinical Cancer Research, 2018, 24, 4854-4864.	7.0	49
21	Phosphatidylinositol 3-kinase Î´ blockade increases genomic instability in B cells. Nature, 2017, 542, 489-493.	27.8	105
22	A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature, 2017, 548, 239-243.	27.8	85
23	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chemical Biology, 2017, 24, 1005-1016.e3.	5.2	109
24	Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. Blood, 2016, 127, 1297-1306.	1.4	26
25	KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. ESMO Open, 2016, 1, e000076.	4.5	19
26	Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene, 2016, 35, 3854-3865.	5.9	37
27	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nature Medicine, 2016, 22, 270-277.	30.7	150
28	DDR1 and Notch: a multifaceted synergy. Translational Cancer Research, 2016, 5, S1551-S1553.	1.0	0
29	Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. Genes and Development, 2015, 29, 690-695.	5.9	51
30	Therapeutic inhibition of <scp>TRF</scp> 1 impairs the growth of p53 â€deficient Kâ€Ras ^{G12V} â€ induced lung cancer by induction of telomeric <scp>DNA</scp> damage. EMBO Molecular Medicine, 2015, 7, 930-949.	6.9	45
31	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunology Research, 2015, 3, 1333-1343.	3.4	42
32	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. Cancer Research, 2014, 74, 6094-6106.	0.9	45
33	Simple and Rapid InÂVivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology. Cell Reports, 2014, 9, 1219-1227.	6.4	186
34	Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. Cancer Research, 2014, 74, 5978-5988.	0.9	30
35	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. Neoplasia, 2013, 15, 511-IN17.	5.3	44
36	PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN. European Journal of Cell Biology, 2012, 91, 662-674.	3.6	19

#	Article	IF	Citations
37	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. Molecular Therapy, 2011, 19, 2201-2212.	8.2	57
38	Expression of IFNÎ³R2 mutated in a dileucine internalization motif reinstates IFNÎ³ signaling and apoptosis in human T lymphocytes. Immunology Letters, 2010, 134, 17-25.	2.5	12
39	Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth. Journal of Biological Chemistry, 2010, 285, 26441-26450.	3.4	25
40	MT1-MMP Is Required for Myeloid Cell Fusion via Regulation of Rac1 Signaling. Developmental Cell, 2010, 18, 77-89.	7.0	108
41	NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells. Cancer Research, 2009, 69, 8611-8619.	0.9	86
42	Leukocyte transmigration is modulated by chemokineâ€mediated PI3KÎ³â€dependent phosphorylation of vimentin. European Journal of Immunology, 2009, 39, 1136-1146.	2.9	59
43	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nature Medicine, 2008, 14, 676-680.	30.7	112
44	The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer, 2008, 8, 11-23.	28.4	792
45	The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation. Cancer Research, 2008, 68, 8899-8907.	0.9	54
46	Human Wrnip1 Is Localized in Replication Factories in a Ubiquitin-binding Zinc Finger-dependent Manner. Journal of Biological Chemistry, 2008, 283, 35173-35185.	3.4	60
47	The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. Cancer Research, 2007, 67, 4278-4286.	0.9	86
48	The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. Journal of Cell Science, 2007, 120, 1859-1867.	2.0	59
49	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase Î³. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14354-14359.	7.1	57
50	Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood, 2006, 107, 689-697.	1.4	127
51	p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood, 2005, 106, 3907-3916.	1.4	72